Latest tweets from Grail

grailbio @grailbio
For Tim, a senior director at GRAIL, fighting cancer is more than just a career. Both his parents were diagnosed wi…
Join GRAIL’s director of growth strategy, Chris Della Porta, at @ZSAssociates 2021 Impact Summit. Learn how we can…
More than 60,000 new cases of leukemia are expected to be diagnosed in the United States in 2021, according to…
What drives you at work? Hear what a member of our Operations team has to say on the topic 👇 To learn more about w…
GRAIL is pleased to partner with the @NHSEngland to investigate the implementation of @GalleriTest. The NHS-Galleri…
Load more

Find out more


To detect cancer early, when it can be cured

There are currently between 14 and 15 million cases of cancer reported globally each year. With such early detection Grail has the potential to save millions of lives in the future – before people even realise anything is wrong.

Grail is a life sciences company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical trials, and state of the art Computer Science and Data Science to enhance the scientific understanding of cancer biology and develop blood tests for early-stage cancer detection.

Grail’s mission is to detect cancer early – even before any symptoms appear. Although not yet fully understood, scientists believe that people who go onto develop cancer initially possess tiny amounts of tumor DNA (ctDNA) in their circulatory systems. If scientists can pick up on this before a tumor develops, the chances of surviving the cancer are greatly increased.

In order to understand this process better, scientists from Grail are collecting vast amounts of this ctDNA data, with the intention of using it to build intelligent prediction models. Once the trials are concluded, it should be possible to develop products which will be able to detect cancer early in asymptomatic individuals, giving people far better odds for being cured.

Effective screening only exists for a few cancer types, meaning most cancer is detected in later stages, when survival rates are much lower. Reliable detection of cancer at an early stage before symptoms appear has the potential to dramatically decrease global cancer mortality.

Investors behind this early-cancer screening project include Bill Gates, Jeff Bezos and genetic analysts Illumina, with total funding currently sitting at $1 billion. The majority of which comes from the $900 million gained in a series B funding round in March this year, with the lead investment from ARCH Venture partners.


Find out more